APEX1 and acute myeloid leukemia: However, 100% of the talazoparib ‘responders’ (MDS#2, CMML#2, AML#1–3) and 83% of the APE1 inhibitor III ‘responders’ (MDS#2, AML#1–3, AML#6) displayed a normal karyotype.